Hummingbird Bioscience Announces Positive Phase I Clinical Data for HMBD-001 Monotherapy Trial at the European Society for Medical Oncology Congress 2023 ...Middle East

HMBD-001 is Hummingbird Bioscience's proprietary anti-HER3 antibody in Phase I/IIa trials in the UK and Phase Ib trials in Australia, targeting multiple solid tumors The clinical data shows that HMBD-001 is safe and well-tolerated with no dose-limiting toxicities and no severe...

Hence then, the article about hummingbird bioscience announces positive phase i clinical data for hmbd 001 monotherapy trial at the european society for medical oncology congress 2023 was published today ( Monday 23/10/2023 - 09:12 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Hummingbird Bioscience Announces Positive Phase I Clinical Data for HMBD-001 Monotherapy Trial at the European Society for Medical Oncology Congress 2023 )

Also on site :

• Inflatable Tanning Pool Loungers Are Going Viral, and Amazon’s ‘Super Comfy’ $28 Version Is a Shopper Favorite
• Quote of the Day: French Novelist Marcel Proust on Gratitude and the People Who Make Our Souls Blossom
• How an Egypt-Argentina World Cup game became a referendum on Palestine